Literature DB >> 2835862

Use of vaccinia virus vectors to study the synthesis, intracellular localization, and action of the human immunodeficiency virus trans-activator protein.

F G Falkner1, T R Fuerst, B Moss.   

Abstract

A recombinant vaccinia virus that expresses the human immunodeficiency virus (HIV) trans-activator (tat) gene was constructed. The tat polypeptide migrated anomalously with an apparent molecular mass of 14 kDa on a sodium dodecyl sulfate-polyacrylamide gel and reacted with polyclonal anti-tat serum. The tat protein was localized predominantly in the cell nucleus despite the absence of other HIV proteins or intranuclear HIV DNA. Additional recombinant vaccinia viruses that contain the Escherichia coli chloramphenicol acetyltransferase (CAT) gene under control of an early vaccinia promoter were constructed. Insertion of the HIV trans-activator-responsive (tar) sequence at the precise start of the CAT mRNA decreased CAT expression slightly. Trans-activation of vaccinia virus-encoded tarCAT failed to occur when CV-1 or HeLa cells were coinfected with the recombinant vaccinia virus expressing tat or when a HeLa cell line containing stably integrated copies of tat was used for infection, indicating the absence of transcriptional or translational effects under these conditions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2835862     DOI: 10.1016/0042-6822(88)90559-4

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Characterization of murine monoclonal antibodies to the tat protein from human immunodeficiency virus type 1.

Authors:  D A Brake; J Goudsmit; W J Krone; P Schammel; N Appleby; R H Meloen; C Debouck
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

2.  Nucleolar and nuclear localization properties of a herpesvirus bZIP oncoprotein, MEQ.

Authors:  J L Liu; L F Lee; Y Ye; Z Qian; H J Kung
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 3.  Vaccinia virus vectors: new strategies for producing recombinant vaccines.

Authors:  D E Hruby
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

4.  HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.

Authors:  S A Migueles; M S Sabbaghian; W L Shupert; M P Bettinotti; F M Marincola; L Martino; C W Hallahan; S M Selig; D Schwartz; J Sullivan; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

5.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

6.  The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences.

Authors:  Stephen A Migueles; Alisha C Laborico; Hiromi Imamichi; W Lesley Shupert; Cassandra Royce; Mary McLaughlin; Linda Ehler; Julia Metcalf; Shuying Liu; Claire W Hallahan; Mark Connors
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

7.  Endocytosis and targeting of exogenous HIV-1 Tat protein.

Authors:  D A Mann; A D Frankel
Journal:  EMBO J       Date:  1991-07       Impact factor: 11.598

Review 8.  Marek's disease herpesvirus transforming protein MEQ: a c-Jun analogue with an alternative life style.

Authors:  J L Liu; H J Kung
Journal:  Virus Genes       Date:  2000       Impact factor: 2.198

9.  A novel use of TAT-EGFP to validate techniques to alter osteosarcoma cell surface glycosaminoglycan expression.

Authors:  Arjuna Kumarasuriyar; Christian Dombrowski; David A Rider; Victor Nurcombe; Simon M Cool
Journal:  J Mol Histol       Date:  2007-09-21       Impact factor: 3.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.